Table 1. Background information and overall survival for all malignant melanoma patients treated with AdCD40L.
| Patient no | Sex | Agea | WHOa | Primary tumor localisation | Injected metastasis | Number of injections | Previous immunological treatment | LDb | Overall survivalc |
|---|---|---|---|---|---|---|---|---|---|
| Without cyclophosphamide | |||||||||
| 1 | F | 72 | 0 | Ocular | Liver | 4 | No | 14.4 | 7 |
| 2 | F | 61 | 1 | Unknown (node) | SC | 4 | Multiferon | ND | 11 |
| 3 | M | 79 | 1 | Ocular | Liver | 4 | No | ND | 13 |
| 4* | F | 68 | 0 | Ocular | Liver | 4 | IGF1 inhibitor | 2.8 | 145 |
| 5 | M | 77 | 0 | Skin | SC | 4 | Interferon | 3.1 | 22 |
| 6 | M | 63 | 0 | Skin | SC | 4 | No | 3.3 | 21 |
| With cyclophosphamide | |||||||||
| 7 | M | 23 | 0 | Ocular | Liver | 8 | No | 3.7 | 43 |
| 8 | F | 67 | 0 | Mucosal (vulva) | Node | 4 | No | 2.6 | 216+ |
| 9 | F | 52 | 0 | Ocular | Parotid | 4 | Methotrexate | 3.0 | 32 |
| 10 | F | 62 | 0 | Ocular | SC | 4 | No | 4.7 | 34 |
| 11 | F | 45 | 1A | Skin | Node | 3 | Multiferon, Ipi | 11.8 | 5 |
| 12 | M | 63 | 1A | Skin | Liver | 4 | Interferon, Ipi | 3.8 | 39 |
| 13 | F | 70 | 0 | Ocular | Liver | 4 | No | 4.6 | 28 |
| 14 | M | 51 | 1A | Skin | SC | 8 | Ipi | 3.5 | 64 |
| 15 | M | 61 | 1 | Ocular | Liver | 4 | No | 3.8 | 13 |
| With cyclophosphamide and irradiation | |||||||||
| 16* | F | 70 | 0 | Ocular | Liver | 4 | AdCD40L | 2.9 | 19 |
| 17 | F | 69 | 0 | Skin | Node | 4 | Ipi | 5.3 | 33 |
| 18 | F | 56 | 0 | Ocular | Liver | 8 | No | 3.4 | 65 |
| 19 | F | 69 | 0 | Skin | Liver | 4 | Pembrolizumab | 4.0 | 45 |
| 20 | M | 55 | 0 | Unknown (node) | SC | 4 | Ipi | 3.2 | 26 |
| 21 | F | 68 | 1A | Skin | SC | 4 | Ipi | 3.2 | 21 |
| 22 | M | 74 | 0 | Mucosal (nasal cavity) | Liver | 3 | No | 2.8 | 17 |
| 23 | M | 55 | 1 | Ocular | Liver | 3 | No | 14.3 | 6 |
| 24 | M | 70 | 0 | Mucosal (perianally) | Adjacent liver | 4 | No | 2.7 | 38 |
Abbreviations: F = female; Ipi = ipilimumab; LD = lactate dehydrogenase; M = male; ND = not done; SC = subcutaneous; WHO pre = performance status at enrollment.
aAt the initiation of treatment
breference interval: 1.9-4.2 ukat/L
cCut-off: 04 Dec 2016, overall survival in weeks (+: still alive)
*= same patient